You are here

Notice of final decisions - ACMS #32, ACCS #29, Joint ACMS-ACCS #26, November 2020 meetings

Scheduling medicines and poisons

22 April 2021

1 Notice of final decisions to amend (or not amend) the current Poisons Standard

This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:

  • decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
  • reasons for those final decisions; and
  • date of effect of those decisions.

2 Final decision in relation to psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine]

Note that the final decision for psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine] are not published in this notice.

Amended timing on the scheduling process for these substances will be published on the TGA website following the completion of the independent review.

Final decisions and reasons

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au (for substances referred to the ACMS or Joint ACCS-ACMS) or chemicals.scheduling@health.gov.au (for substances referred to the ACCS).

Contents

  • 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
  • 2 Final decision in relation to psilocybin and MDMA [N, α-Dimethyl-3,4-(methylenedioxy)phenylethylamine]
  • 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #32, November 2020)
    • 3.1 Final decision in relation to amygdalin and hydrocyanic acid
    • 3.2 Final decision in relation to bilastine
    • 3.3 Final decision in relation to budesonide and formoterol
  • 4 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #29, November 2020)
    • 4.1 Final decision in relation to azoxystrobin
    • 4.2 Final decision in relation to triticonazole
  • 5 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #26, November 2020)
    • 5.1 Final decision in relation to azelaic acid
    • 5.2 Final decision in relation to 2-hydroxyethyl methacrylate (2-HEMA)
    • 5.3 Final decision in relation to magnesium hydroxide
    • 5.4 Final decision in relation to tetrahydrofurfuryl alcohol
    • 5.5 Final decision in relation to cannabidiol (private application